Skip to main content

Advertisement

SpringerLink
Log in

The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Preoperative or neoadjuvant chemotherapy is an option in patients with large operable breast cancer to facilitate the breast conservation and to downstage the disease to make inoperable breast cancer to operable one. It is also called the window of opportunity; it provides a unique opportunity to derive biological information related to tumor response. Neoadjuvant chemotherapy has been compared with standard, postoperative adjuvant chemotherapy with goals of improving survival and facilitating local therapies. Unfortunately, neoadjuvant chemotherapy does not seem to improve overall survival. There is a lack of data from India regarding the neoadjuvant chemotherapy. The present study was carried out to assess the response to neoadjuvant chemotherapy in breast cancer.

Materials and methods

We retrospectively analyzed the records of patients who were started on neoadjuvant chemotherapy (NACT) at our center for 1 year (August 2012 to July 2013). Case files were thoroughly reviewed, and patient’s characteristics (age, pre-/postmenopausal status, family history of breast/ovarian/other cancer), mode of detection, treatment, and histological features were analyzed.

Results

Out of 322 patients with breast cancer registered in our institute, 80 patients received neoadjuvant chemotherapy. Median age was 45 years. The most common presentation was left-sided breast lump (Lt > Rt) with a median duration of symptoms was 4 months. Postmenopausal patients (53.75 %) were more than premenopausal (46.25 %). Seventy-two patients were stage III and 8 were stage II disease. Bilateral breast cancer was seen in 8 patients. Most common histological type was invasive ductal carcinoma (95 %). Estrogen receptor (ER) and/or progesterone (PR) positive were seen in 47 (58.75 %) patients. Ten patients were HER2 positive and ER/PR negative, and 5 patients were triple positive. Triple-negative patients were 22 (27.5 %). The most common neoadjuvant chemotherapy protocol used was FEC. Clinical response before surgery was CR 13 %, PR 68.68 %, stable disease 11.62 %, and progressive disease 4.65 %. Pathological CR was seen in 6.9 % of tumors. Nodal status at surgery was ypN0-40 %, ypN1-28. 5 %. ypN2-27 %, and ypN3-4.28 %.

Conclusion

In a population of predominantly locally advanced patients, NACT with anthracyclines yielded pCR rates comparable to published studies. There were a high proportion of HER2-positive patients, most of whom could not receive anti-HER2 therapy due to financial reasons.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T et al (2003) Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 14:227–232

    Article  PubMed  CAS  Google Scholar 

  • Charehbili A, Fontein DB, Kroep JR et al (2014) Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev 40:86–92

    Article  PubMed  CAS  Google Scholar 

  • Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106

    Article  PubMed  CAS  Google Scholar 

  • Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N et al (2012) Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Cancer Res 72(24 Suppl):S1–S11; Abstract nr

  • Danforth DN Jr, Lippman ME, McDonald H et al (1990) Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg 56:6–11

    PubMed  Google Scholar 

  • Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716

    Article  PubMed  CAS  Google Scholar 

  • Deo SV, Bhutani M, Shukla NK, Raina V, Rath GK, Purkayasth J (2003) Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J Surg Oncol 84(4):192–197

    Article  PubMed  CAS  Google Scholar 

  • Erol K, Baltali E, Altundag K, Guler N, Ozisik Y, Onat DA et al (2005) Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. Onkologie 28:81–85

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493

    PubMed  CAS  Google Scholar 

  • Ghosh I, Dabkara D, Dwary A, Ahmed R (2013) Neoadjuvant Chemotherapy (NAC) for breast cancer—preliminary experience from a tertiary cancer center in India. Ann Oncol 24(Supplement 3):19–22. doi:10.1093/annonc/mdt081.8

    Google Scholar 

  • Gralow JR, Burstein HJ, Wood W et al (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814–819

    Article  PubMed  Google Scholar 

  • Gupta S, Bharat R, Shet T, Desai SB, Patil VM, Bakshi A, Parmar V, Badwe RA (2012) Single agent weekly paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a feasibility study. Clin Oncol 24:604–609

    Article  CAS  Google Scholar 

  • Hortobagyi GN, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507–2516

    Article  PubMed  CAS  Google Scholar 

  • Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P et al (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24:1831–1838

    Article  PubMed  CAS  Google Scholar 

  • Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469

    PubMed  CAS  Google Scholar 

  • Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. JCO 26(8):1275–1281

    Article  Google Scholar 

  • Patel T, Gupta A, Shah M (2013) Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracycline-based neoadjuvant chemotherapy. J Cancer Res Ther 9:245–249

    Article  PubMed  Google Scholar 

  • Raina V, Kunjahari M, Shukla NK, Deo S, Sharma A, Mohanti BK, Sharma DN (2011) Outcome of combined modality treatment including neoadjuvant chemotherapy of 128 casesof locally advanced breast cancer : data from a tertiary cancer center in northern India. Indian J Cancer 48:80–85

    Article  PubMed  CAS  Google Scholar 

  • Redkar AA, Kabre SS, Mitra I (1992) Estrogen and progesterone receptors measurement in breast cancer with enzyme-immunoassay and correlation with other prognostic factors. Indian J Med Res 96:1–8

    PubMed  CAS  Google Scholar 

  • Schott AF, Roubidoux MA, Helvie MA et al (2005) Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92:231–238

    Article  PubMed  CAS  Google Scholar 

  • Schwartz GF, Birchansky CA, Komarnicky LT et al (1994) Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362–369

    Article  PubMed  CAS  Google Scholar 

  • Sedlmayer F, Sautter-Bihl ML, Budach W, Dunst J, Fastner G, Feyer P et al (2013) DEGRO practical guidelines:radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol 189:825–833

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Segal R, Dent SF, Verma S, Gerller S, Young V, Goel R et al (2006) Changing demographics of locally advanced breast cancer: data from a regional cancer centre. ASCO

  • Semiglazov V, Eiermann W, Zambetti M et al (2011) Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol 37:856–863

    Article  PubMed  CAS  Google Scholar 

  • Singletary SE, McNeese MD, Hortobagyi GN (1992) Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69:2849–2852

    Article  PubMed  CAS  Google Scholar 

  • van der Hage JA, van de Velde CJ, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224–4237

    PubMed  Google Scholar 

  • von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W et al (2013) Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31(29):3623–3630

    Article  Google Scholar 

Download references

Conflict of interest

All authors have declared no conflict of interest.

Author information

Authors and Affiliations

  1. No. 5, OPD Blocks, Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Banglore, 560029, Karnataka, India

    Umesh Das, K. C. Lakshmaiah, K. Govind Babu, T. M. Suresh, D. Lokanatha, Linu Jacob & Suresh Babu

Authors
  1. Umesh Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. C. Lakshmaiah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Govind Babu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. M. Suresh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Lokanatha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Linu Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Suresh Babu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Umesh Das.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Das, U., Lakshmaiah, K.C., Govind Babu, K. et al. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India. J Cancer Res Clin Oncol 140, 1777–1782 (2014). https://doi.org/10.1007/s00432-014-1724-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1724-1

Keywords

Search

Navigation